# A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

> **NCT05701800** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 659 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** mRNA-1468
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT05701800
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 659 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701800, "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05701800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*